Prevalence and progression of chronic kidney disease among p
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Researchers report the prevalence and change in severity of chronic kidney disease (CKD) in DISCOVER, a global, 3 year, prospective, observational study of patients with type 2 diabetes (T2D) initiating second?line glucose-lowering therapy. CKD stages were defined according to estimated glomerular filtration rate (eGFR).

Overall, 7843 patients from 35 countries had a baseline serum creatinine measurement. Of these (56.7% male; mean age: 58.1 years; mean eGFR: 87.5 mL/min/1.73m2), baseline prevalence estimates for stage 0–1, 2, 3, and 4–5 CKD were 51.4%, 37.7%, 9.4%, and 1.4%, respectively.

A total of 5819 patients (74.2%) also had at least one follow-up serum creatinine measurement (median time between measurements: 2.9 years). Mean eGFR decreased slightly to 85.7 mL/min/1.73m2 over follow-up. CKD progression (increase of more than 1 stage) occurred in 15.7% of patients, and regression (decrease of more than 1 stage) in 12.0%.

In summary, a substantial proportion of patients with T2D developed CKD or had CKD progression after the initiation of second-line therapy. Renal function should be regularly monitored in these patients, to ensure early CKD diagnosis and treatment.

Source: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14401?af=R
Like
Comment
Share